Patents by Inventor Yajin Ni

Yajin Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249556
    Abstract: Provided herein are improved methods for transducing immune cells, such as T cells, with retroviral vectors to express exogenous gene products, such as chimeric antigen receptors (CARs). Provided herein are methods that increase transduction efficiency thereby increasing the percentage of immune cells in a population expressing the exogenous gene product. Associated cells, cell populations, compositions and methods of use are also provided.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 11, 2022
    Inventors: Todd LUMAN, Josergio ZARAGOZA, Abraham GERMANSDERFER, Suma RAO, Yajin NI, Chupei ZHANG, Tom Tao HUANG
  • Publication number: 20220241329
    Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.
    Type: Application
    Filed: February 3, 2022
    Publication date: August 4, 2022
    Inventors: Muneeswara Babu MEDI, Zhuojin XU, Jung S. LEE, Yajin NI, Mark W. LEONARD
  • Publication number: 20210062150
    Abstract: Provided herein are methods for preparing T cells for T cell therapy comprising contacting a cell population at a predetermined cell density, with a concentration of an anti-CD3/CD28 nanomatrix and culturing the cells thereby producing a T cell population comprising an increased percentage of at least one T cell subtype. In some embodiments, the method increases the percentage of stem memory T cells.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 4, 2021
    Inventors: Yajin NI, Chupei ZHANG, Mark W. LEONARD, Thomas Charles PERTEL
  • Publication number: 20200317780
    Abstract: Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR? cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 8, 2020
    Inventors: Yajin NI, Hongxiu NING, Janet M. LEE, Mark W. LEONARD
  • Patent number: 8778653
    Abstract: A method for purification of viral compositions is provided. In particular, a method for reduction of unwanted residual DNA in a viral composition while retaining the immunogenicity of the virus itself is provided. The resulting immunogenic viral composition is substantially free of residual DNA, and is useful for the manufacture of medical products, such as vaccines designed for human or animal.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: July 15, 2014
    Assignee: Yisheng Biopharma Holdings Ltd.
    Inventors: Yi Zhang, Jinming Dai, Yajin Ni
  • Publication number: 20130203152
    Abstract: A method for purification of viral compositions is provided. In particular, a method for reduction of unwanted residual DNA in a viral composition while retaining the immunogenicity of the virus itself is provided. The resulting immunogenic viral composition is substantially free of residual DNA, and is useful for the manufacture of medical products, such as vaccines designed for human or animal.
    Type: Application
    Filed: August 12, 2010
    Publication date: August 8, 2013
    Applicant: YISHENG BIOPHARMA HOLDINGS LTD.
    Inventors: Yi Zhang, Jinming Dai, Yajin Ni
  • Patent number: 8043611
    Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 25, 2011
    Assignee: Virxsys Corporation
    Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
  • Publication number: 20110207226
    Abstract: The present invention provides for a hybrid vector system for the purpose of therapeutic gene delivery where the system is used for a targeted integration of a therapeutic gene into a genome. The hybrid vector system comprises a hybrid vector made up of a non-integrating lentiviral vector and an adeno-associated vector, and a therapeutic gene.
    Type: Application
    Filed: August 20, 2009
    Publication date: August 25, 2011
    Applicant: Virxsys Corporation
    Inventors: Yajin NI, Jenice G. D' Costa, Ramdall K. Merling
  • Publication number: 20060121579
    Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.
    Type: Application
    Filed: December 13, 2004
    Publication date: June 8, 2006
    Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
  • Publication number: 20060003452
    Abstract: The invention relates to a method of increasing vector transduction in target cells. The invention provides for the recombinant engineering of a packaging cell line to be capable of expressing one or more membrane proteins which facilitate binding to, and activation of, a target cell. The invention also provides for recombinant engineering of a cell that endogenously expresses one or more such membrane proteins into a packaging cell line. A vector packaged into viral particles via use of such cell lines would comprise an outer envelope containing these proteins. The particles would be specifically suited for binding and targeting to a target cell to facilitate transduction thereof with the vector. The target cell may also be simultaneously activated (stimulated) by the packaged vector in the absence of exogenously supplied stimulatory molecules.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 5, 2006
    Applicant: VIRxSYS Corporation
    Inventors: Laurent Humeau, Vladimir Slepushkin, Brian Paszkiet, Yajin Ni
  • Patent number: 6835568
    Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: December 28, 2004
    Assignee: Virxsys Corporation
    Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
  • Publication number: 20030087419
    Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.
    Type: Application
    Filed: October 30, 2001
    Publication date: May 8, 2003
    Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic